Paidofen 150 ml strawberry - fever and mild to moderate pain

Product Description

Strawberry-flavored syrup for fever and mild to moderate pain in children

Indications

Paidofen children is indicated for the symptomatic treatment of fever and mild to moderate pain.

Composition

Active ingredients - Each ml of oral suspension contains: ibuprofen 20 mg.

Excipients - Excipients with known effect: Sodium 2.03 mg, liquid maltitol 753.30 mg. For the full list of excipients, see section 6.1. of the package leaflet

Citric acid monohydrate, sodium citrate, acesulfame potassium, xanthan gum, sodium benzoate, strawberry flavoring, liquid maltitol, glycerin, purified water

Directions for use and Dosage

The daily dose is structured according to the weight and age of the patient. Undesirable effects can be minimized by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms (see section 4.4 of the package leaflet). In children aged between 3 and 6 months, limit administration to those weighing more than 5.6 kg. The daily dose of 20-30 mg/kg of body weight, divided 3 times a day at intervals of 6-8 hours, can be administered according to the following schedule.

In case of post-vaccination fever, refer to the dosage indicated above, administering a single dose followed, if necessary, by another dose after 6 hours. Do not administer more than 6 hours. Two doses within 24 hours. Consult your doctor if the fever does not decrease. The product is intended for short-term treatment. Consult your doctor if symptoms persist for more than three days. In children under six months of age, consult your doctor if symptoms persist after 24 hours of treatment.

Method of administration: Oral administration to infants and children aged 3 months to 12 years should be done using the measuring syringe provided with the product. The graduated scale on the body of the syringe clearly shows the notches for the different dosages; in particular the 2.5 ml mark corresponding to 50 mg of ibuprofen and the 5 ml mark corresponding to 100 mg of ibuprofen.

Instructions for using the dosing syringe:

• Unscrew the cap by pushing it downwards and turning it to the left.
• Insert the tip of the syringe fully into the hole in the undercap.
• Shake well.
• Turn the bottle upside down, then, holding the syringe firmly, gently pull the plunger downwards, allowing the suspension to flow into the syringe up to the mark corresponding to the desired dose.
• Return the bottle to an upright position and remove the syringe by gently turning it.
• Insert the tip of the syringe into the child's mouth and apply gentle pressure to the plunger to allow the suspension to flow out.
• After use, screw the cap to close the bottle and wash the syringe with hot water. Let it dry, keeping it out of the reach and sight of children.

Warnings

Read the package leaflet carefully before starting treatment.

After three days of treatment without appreciable results, consult your doctor. Undesirable effects can be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see paragraphs below on gastrointestinal and cardiovascular risks). The use of PAIDOFEN should be avoided in conjunction with NSAIDs, including selective COX-2 inhibitors. Analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to this type of drug. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after using other analgesics, antipyretics, nonsteroidal anti-inflammatory drugs and in subjects with bronchial hyperreactivity (asthma), nasal polyps or previous episodes of angioedema (see sections 4.2 and 4.8). Gastrointestinal bleeding, ulceration and perforation: gastrointestinal bleeding, ulceration and perforation, which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal (see section 4.2). The risk of gastrointestinal bleeding, ulceration or perforation is greater in the elderly and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3). high with increased doses of NSAIDs. These patients should initiate treatment on the lowest available dose. Concomitant use of protective agents (e.g., misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients taking low-dose aspirin or other drugs likely to increase gastrointestinal risk (see section 4.5). Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or anti-platelet agents such as aspirin (see section 4.5).

Storage

For storage conditions after first opening, see section 6.3. of the package leaflet

Format

150 ml bottle